Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

BioDiem granted European patent for antimicrobial drug

Australian vaccine development company BioDiem Ltd (ASX: BDM) announced today the successful granting of a key European patent for its synthetic antimicrobial compound BDM-I. BDM-I is a novel compound active against a range of pathogenic micro-organisms including bacteria, fungi and protozoa. The patent provides protection around BDM-I as a treatment for vulvovaginitis, a general term for inflammation of the vulva or vagina.

7 Aug 2012

New research center to expedite study of gene transfer approach

In an alliance aimed at bringing a new, personalized immunotherapy approach to patients with a wide variety of cancers, the University of Pennsylvania and Novartis announced today an exclusive global research and licensing agreement to further study and commercialize novel cellular immunotherapies using chimeric antigen receptor (CAR) technologies.

6 Aug 2012

Mylan launches 18 antiretroviral products in India to treat HIV/AIDS

Mylan Inc., one of the world's leading generic and specialty pharmaceutical companies, today announced that its subsidiary, Mylan Pharmaceuticals Private Limited, has commenced commercial operations in India, starting with the launch of a comprehensive portfolio of 18 antiretroviral (ARV) products for the treatment of HIV/AIDS.

6 Aug 2012

Novartis, Penn partner to study and commercialize novel cellular immunotherapies for cancer

6 Aug 2012

Helix BioMedix second quarter revenue decreases 32% to $471,000

Helix BioMedix, Inc., a developer of bioactive peptides, today announced financial results for the second quarter ended June 30, 2012.

3 Aug 2012

Gilead Sciences signs deals with 3 Indian pharmaceutical companies to promote low-cost HIV drugs in developing countries

Gilead Sciences Inc. announced Thursday that it plans to partner with Mylan Inc., Ranbaxy Laboratories Ltd. and Strides Arcolab Ltd. "to promote access to high-quality, low-cost generic versions of Gilead's HIV medicine emtricitabine in developing countries," the Wall Street Journal reports.

3 Aug 2012

Toshiba establishes Chinese Procurement Center in Shanghai

Toshiba Medical Systems Corporation has established the Chinese Procurement Center in Shanghai.

3 Aug 2012

Health law's medical-loss ratio and birth control coverage requirements kick in today

Aug. 1 marks the deadline for insurers to refund consumers and employers if they didn't spend at least 80 percent of premiums on health care. Another provision takes effect requiring most employers to include contraceptive and other women's health services without copays in the insurance plans they offer workers.

2 Aug 2012

OrPro to advance development of ORP-100 for treatment of cystic fibrosis

OrPro Therapeutics, Inc. today announced that the company has been awarded a National Heart, Lung and Blood Institute Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH).

31 Jul 2012

InSite Vision second quarter total revenues decrease to $1.8 million

InSite Vision Incorporated today reported financial results for the quarter ended June 30, 2012.

31 Jul 2012

Australia's top medical researchers for 2012 announced

Finalists for one of Australia’s longest running and most prestigious awards for medical research were announced today. This year’s winner will join a list of alumni winners that includes many of the country’s most respected scientists.

31 Jul 2012

Harris reports revenue of $1.44 billion for fourth quarter 2012

Harris Corporation (NYSE:HRS) reported revenue in the fourth quarter of fiscal 2012 of $1.44 billion compared with $1.52 billion in the prior-year quarter.

31 Jul 2012

New research indicates molecular signaling from end to end in peripheral nerve cells

When the longest cells in the body are injured at their farthest reaches, coordinating the cells' repair is no easy task. This is in part because these peripheral nerve cells can be extremely long - up to one meter in adult humans - which is a lot of distance for a molecular distress signal to cover in order to reach the "command center" of the cell's nucleus.

30 Jul 2012

Progress with GSK in advancing VaxiRNA technology earns Alnylam $3.2M milestone payment

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has earned a development milestone payment from GlaxoSmithKline, totaling $3.2 million. The milestone payment is related to progress in the companies' collaboration on the use of VaxiRNA technology for the production of GSK influenza vaccine.

30 Jul 2012

Neurotez receives U.S. patent for Leptin to treat Alzheimer's

Neurotez, Inc. today announced the grant of U.S. Patent number 8,227,408 by the United States Patent and Trademark Office covering the company's lead product candidate, Leptin. The patent protects use of the hormone Leptin for treating a progressive cognitive disease, disorder or condition, such as Alzheimer's disease (AD), resulting from accumulation of an amyloid peptide or for improving resilience of cognitive function by modulating the accumulation of the amyloid peptide in brain.

30 Jul 2012

Study validates importin beta1 protein's crucial role in nerve repair

Several years ago, Prof. Michael Fainzilber and his group in the Biological Chemistry Department made a surprising discovery: Proteins thought to exist only near the cell nucleus could also be found in the far-off regions of the body's longest cells - peripheral nerve cells that extend processes called axons, reaching up to a meter in length in adult humans.

27 Jul 2012

Greatbatch second quarter 2012 sales increase 14% to $166.5 million

Greatbatch, Inc., today announced results for its second quarter ended June 29, 2012.

26 Jul 2012

bluebird bio completes $60 million Series D financing

bluebird bio, a leader in the development of innovative gene therapies for severe genetic disorders, today announced the successful completion of a $60 million Series D financing. In this round, new investors Deerfield Partners, RA Capital, Ramius Capital Group, and two undisclosed blue chip public investment funds joined existing investors ARCH Venture Partners, Third Rock Ventures, TVM Capital, and Forbion Capital Partners. In addition, Shire plc joined the round as a strategic investor.

25 Jul 2012

Encision first quarter 2013 revenue decreases to $3.1 million

Encision Inc., a medical device company owning patented surgical technology that is emerging as a standard of care in minimally-invasive surgery, today announced financial results for its fiscal 2013 first quarter ended June 30, 2012.

25 Jul 2012